New Dosages of Inflammatory Markers for the Early Diagnosis of Nosocomial Bacterial Infections of the Newborn
- Conditions
- Nosocomial Infection
- Registration Number
- NCT00701948
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
This study aims to evaluate new dosage of inflammatory markers or new inflammatory markers for the diagnosis of nosocomial bacterial infection. We made the hypothesis that these new dosages or new inflammatory markers could be more useful than dosage of inflammatory markers already used in clinical practice (especially the use of a combination of interleukins (6 or 8) and C-reactive protein for the management of newborns with a clinical suspicion of nosocomial bacterial infection and especially could allow to avoid excessive treatment with antibiotics
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 240
- Newborns > 72 hours of life hospitalized in neonatal intensive or intermediate care unit presenting a clinical suspicion of NBI
- Early post-operative period ( surgery of less than 48 hours)
- Multiple malformations
- Newborn already included in the study for a previous septic events
- Newborn treated with antibiotics in the last 24 hours
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of new dosage of inflammatory markers or new inflammatory markers for the diagnosis of nosocomial bacterial infection. 48 hours and at 72 hours
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Service de Pédiatrie 2 - Hôpital d'Enfants CHU de Dijon; 10 - bld Maréchal de Lattre de Tassigny
🇫🇷Dijon, France
Service de Pédiatrie 2 - Hôpital de Hautepierre; 1 - Avenue Molière
🇫🇷Strasbourg, France